Armistice Capital, LLC Aligos Therapeutics, Inc. Transaction History
Armistice Capital, LLC
- $7.69 Billion
- Q2 2024
A detailed history of Armistice Capital, LLC transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 7,256,410 shares of ALGS stock, worth $68.2 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
7,256,410
Previous 6,893,410
5.27%
Holding current value
$68.2 Million
Previous $6.76 Million
62.41%
% of portfolio
0.03%
Previous 0.09%
Shares
3 transactions
Others Institutions Holding ALGS
# of Institutions
46Shares Held
47.2MCall Options Held
1.4KPut Options Held
300-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$60.1 Million0.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$57.4 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5MShares$47 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$33.3 Million0.18% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.12MShares$29.3 Million0.03% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $373M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...